Has the French Biotech Industry valuation changed over the past few years?

Investors are optimistic on the French Biotechs industry, and appear confident in long term growth rates. The 3-year average PS ratio of 8.8x is lower than the industry's current PS ratio of 21.6x.

Which industries have driven the changes within the French Healthcare industry?

There are no additional sub-industries under this industry.

French (CAC) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 21 Sep 2026	€10.5b	€483.3m	-€903,347,835.52	16.5x	-11.6x	21.6x
Wed, 19 Aug 2026	€11.8b	€482.8m	-€902,621,608.76	16.5x	-13x	24.4x
Fri, 17 Jul 2026	€13.0b	€507.5m	-€879,915,543.96	19.6x	-14.7x	25.6x
Sun, 14 Jun 2026	€9.4b	€495.2m	-€860,613,195.80	18.6x	-10.9x	18.9x
Tue, 12 May 2026	€11.4b	€517.9m	-€834,516,270.03	16.6x	-13.6x	21.9x
Thu, 09 Apr 2026	€10.8b	€502.4m	-€819,905,789.82	13.6x	-13.2x	21.5x
Sat, 07 Mar 2026	€10.8b	€561.4m	-€763,865,518.53	13x	-14.1x	19.2x
Mon, 02 Feb 2026	€10.7b	€559.2m	-€762,651,295.58	13.5x	-14x	19.1x
Wed, 31 Dec 2025	€11.8b	€641.3m	-€693,542,197.64	9.9x	-17x	18.4x
Fri, 28 Nov 2025	€2.7b	€637.2m	-€431,419,936.25	10.5x	-6.2x	4.2x
Sun, 26 Oct 2025	€2.5b	€637.2m	-€407,294,787.85	10.1x	-6.1x	3.9x
Tue, 23 Sep 2025	€2.4b	€661.5m	-€411,732,322.46	15.4x	-5.7x	3.6x
Thu, 21 Aug 2025	€2.6b	€674.0m	-€445,820,214.03	15.4x	-5.9x	3.9x
Sat, 19 Jul 2025	€2.0b	€656.2m	-€453,401,230.40	15.7x	-4.4x	3x
Mon, 16 Jun 2025	€2.0b	€667.0m	-€496,161,087.76	17.4x	-4.1x	3x
Wed, 14 May 2025	€2.5b	€668.3m	-€664,593,426.58	39.5x	-3.7x	3.7x
Fri, 11 Apr 2025	€2.1b	€651.5m	-€551,176,026.69	13.9x	-3.8x	3.2x
Sun, 09 Mar 2025	€2.5b	€650.9m	-€520,074,581.40	16.6x	-4.7x	3.8x
Tue, 04 Feb 2025	€2.4b	€650.6m	-€528,652,278.25	16.5x	-4.5x	3.7x
Thu, 02 Jan 2025	€2.3b	€650.5m	-€527,914,717.80	17.4x	-4.4x	3.6x
Sat, 30 Nov 2024	€2.4b	€654.2m	-€547,728,212.22	18.5x	-4.4x	3.7x
Mon, 28 Oct 2024	€2.8b	€641.4m	-€519,729,339.94	18.6x	-5.4x	4.4x
Wed, 25 Sep 2024	€3.0b	€545.4m	-€590,566,075.56	28.1x	-5x	5.4x
Fri, 23 Aug 2024	€3.1b	€520.3m	-€579,601,079.39	37.2x	-5.3x	5.9x
Sun, 21 Jul 2024	€2.9b	€511.7m	-€566,393,417.73	28.9x	-5.1x	5.7x
Tue, 18 Jun 2024	€2.9b	€514.3m	-€569,127,812.90	26.2x	-5.2x	5.7x
Thu, 16 May 2024	€3.3b	€502.3m	-€592,212,872.69	27.6x	-5.6x	6.6x
Sat, 13 Apr 2024	€3.3b	€515.7m	-€629,475,775.73	28.4x	-5.2x	6.3x
Mon, 11 Mar 2024	€3.1b	€567.8m	-€647,028,952.54	21.5x	-4.8x	5.5x
Wed, 07 Feb 2024	€3.0b	€559.0m	-€675,251,139.78	22x	-4.5x	5.4x
Fri, 05 Jan 2024	€3.2b	€594.2m	-€683,018,726.00	23x	-4.7x	5.4x
Sun, 03 Dec 2023	€3.2b	€594.5m	-€684,435,706.00	21.8x	-4.6x	5.3x
Tue, 31 Oct 2023	€3.1b	€803.3m	-€566,482,060.00	21.6x	-5.4x	3.8x
Thu, 28 Sep 2023	€3.5b	€876.5m	-€620,916,779.00	14.8x	-5.7x	4x


FR Market	-1.30%
Healthcare	-2.15%
Biotech	-8.04%
Biotech	-8.04%

Company	Last Price	7D	1Y	Valuation
ALERS Eurobio Scientific Société anonyme	€25.20	23.5% +€48.3m	-1.2%	PE52.2x
ABNX ABIONYX Pharma	€1.83	8.0% +€5.8m	-52.8%	PS19x
ADOC Adocia	€3.65	2.9% +€2.0m	-56.4%	PS18.6x
ALTME TME Pharma	€0.11	15.4% +€1.4m	17.5%	PE-3.3x
IPH Innate Pharma	€1.58	0.8% +€1.1m	0%	PS15.1x

Announcement • Sep 09

Inventiva Presents Multiple Abstracts on Lanifibranor At Paris MASH 2026

Inventiva announced the presentation of five abstracts at the 12th Paris MASH Meeting taking place September 10-11, 2026, at the Pasteur Institut in Paris, France. The abstracts present Phase 1 and Phase 2 clinical and preclinical data that further characterize the pan-PPAR pharmacological profile of lanifibranor and evaluate its potential effects on systemic metabolic dysfunction associated with MASH. Clinical data from Phase 1 and Phase 2 trials demonstrated direct PPAR target engagement, as reflected by increases in adiponectin, together with improvements observed in measures of insulin sensitivity, glycemic control, lipid parameters, and selected cardiovascular risk factors, with effects observed in patients with or without Type 2 diabetes. Separate preclinical studies demonstrated improvement in hepatic and metabolic parameters, and further characterized lanifibranor’s balanced pan-PPAR pharmacology, supporting a differentiated fluid and cardiac profile within the PPAR class. Lanifibranor is currently being evaluated in the Phase 3 NATiV3 clinical trial for the treatment of patients with MASH with moderate and advanced fibrosis, with topline results expected in the fourth quarter of this year. Following are the details of the poster presentations on September 10, 2026: Abstract Title: Beyond The Liver: Cardiovascular Effects of The Pan-PPAR Agonist Lanifibranor in Patients With MASH, Publication Number: 1256, Authors: S. Francque, A. Holleboom, J. Campagna, S. Hogan, G. Wettstein, M. Abedelmalek; Abstract Title: Metabolic Benefits of Pan-PPAR Agonist Lanifibranor in Patients With and Without Type 2 Diabetes, Publication Number: 1249, Authors: A. Holleboom, M. Abdelmalek, S. Hogan, J. Campagna, G. Wettstein, S. Francque; Abstract Title: Lanifibranor Improves Metabolic and Histological Features of MASH Across Multiple Preclinical Models: Convergent Pan-PPAR Activity, Publication Number: 1255, Authors: A. Holleboom, S. Francque, J. Campagna, S. Hogan, G. Wettstein, M. Abedelmalek; Abstract Title: Lanifibranor Phase 1/2A Experience – PPAR Engagement and Metabolic Activity Without Early Clinical Fluid Retention, Publication Number: 1254, Authors: A. Holleboom, S. Hogan, J. Campagna, G. Wettstein, M. Abdelmalek, S. Franque; Abstract Title: Partial PPAR Agonism Underlies Lanifibranor's Preclinical Fluid/Cardiovascular Safety Versus Full and Dual PPAR Agonists, Publication Number: 1344, Authors: S. Francque, A. Holleboom, J. Campagna, S. Hogan, G. Wettstein, M. Abedelmalek. Lanifibranor, Inventiva’s lead product candidate, is an orally available small molecule that acts to induce antifibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor (“PPAR”) isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARa and PPARd, and a partial activation of PPAR?. Lanifibranor is the only pan-PPAR agonist in clinical development for the treatment of MASH. Inventiva believes that lanifibranor’s moderate and balanced pan-PPAR binding profile contributes to the favorable tolerability profile that has been observed in clinical trials and preclinical studies to date. The FDA has granted Breakthrough Therapy and Fast Track designation to lanifibranor for the treatment of MASH. Lanifibranor is an investigational medicine and has not been approved for use by any regulatory authority. Its safety and efficacy have not been established.

Announcement • Jul 16

Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update

Valerio Therapeutics entered into a binding term-sheet with Abivax, setting out the principal terms of an exclusive worldwide research and development collaboration. The final terms remain subject to the signing of the definitive co-ownership and license agreement. In connection with this collaboration, Valerio Therapeutics and Abivax will work together to identify, design and evaluate next-generation therapeutic candidates for immune-mediated inflammatory diseases, leveraging Abivax’s expertise in this area together with Valerio Therapeutics' targeted technology platforms. The collaboration will include the generation, manufacturing and preclinical evaluation of research candidates. The candidates will be evaluated for their therapeutic potential and may be further developed by Abivax. Under the terms of the binding term-sheet, Valerio Therapeutics will receive an upfront payment up to approximately EUR 2.4 million and would be eligible to receive development and commercial milestone payments, as well as royalties on net sales and sublicensing revenues, subject to the execution of the definitive co-ownership and license agreement and the achievement of specified milestones and other terms. For Valerio Therapeutics, the execution of this binding term-sheet represents an important milestone in the evolution of the Company as a precision RNA therapeutics developer with a growing pipeline. The partnership with Abivax will provide non-dilutive funding to support pipeline advancement, will supplement the existing potential for future milestone and royalty revenues and will reinforce the attractiveness of Valerio Therapeutics’ technology platform to biotech and pharmaceutical partners. This transaction is aligned with Valerio Therapeutics’ strategy of advancing a focused portfolio of wholly owned therapeutic programs while complementing these efforts through partnerships and licensing transactions that leverage its platform capabilities and create additional value creation opportunities. Valerio Therapeutics will provide further updates in due course, including upon signature of the definitive co-ownership and license agreement, in accordance with its obligations under the binding term-sheet and applicable regulatory obligations. Valerio Therapeutics is advancing a pipeline of precision RNA therapeutics focused on diseases where targeted delivery to specific immune cells enables differentiated treatment approaches. The Company’s lead programs have been selected based on a combination of strong disease biology, clear unmet medical need and the ability to leverage Valerio Therapeutics’ proprietary V-Body platform to direct RNA-based payloads to disease-relevant tissue. The proprietary pipeline currently includes the lead program VTX-001 in ankylosing spondylitis, VTX-002 in IgG4-related disease and VTX-003 in oncology. VTX-001 and VTX-002 are next-generation in vivo CAR-T approaches in the immunity & inflammation field and are designed to selectively deplete pathogenic immune-cell populations, while VTX-003 uses a V-Body–oligonucleotide conjugate approach to deliver siRNA to reactivate exhausted T cells in oncology. Valerio Therapeutics’ platform is designed to accelerate discovery and development by enabling rapid generation of tailored V-Bodies, which can be combined with RNA payloads and next-generation lipid nanoparticle technologies across multiple therapeutic modalities. The Company's strategy and pipeline reflect a milestone-driven approach to value inflection, with the ambition to nominate up to two development candidates within 12 to 18 months and to progress at least one program into first-in-human clinical studies within 18 to 24 months.

French (CAC) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Innate Pharma S.A. (EPA:IPH) Just Reported And Analysts Have Been Lifting Their Price Targets

New major risk - Share price stability

MaaT Pharma Provides Update On MaaT013 (Xervyteg) Development Plan Following CHMP Negative Opinion

Sensorion Announces Registration And Connection Details For SENS-601 Program Day And Provides Updates On SENS-601 And SENS-401 Product Pipeline

No longer forecast to breakeven

New minor risk - Share price stability

Adocia Presents Data On AdoShell Platform Scalability And BioChaperone Lispro Phase 3 Results

Price target decreased by 8.5% to €9.83

Inventiva Presents Multiple Abstracts on Lanifibranor At Paris MASH 2026

New minor risk - Shareholder dilution

VLA: Lyme Vaccine Progress And 2026 Earnings Outlook Will Drive Repricing

New minor risk - Share price stability

Valerio Therapeutics Enters into Binding Term-Sheet with Abivax for Exclusive Global Research and Development Collaboration and Provides Pipeline Update

GENFIT Reports Positive Phase 1B Data for GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma

genOway Société anonyme, Annual General Meeting, Jun 26, 2026

New minor risk - Financial data availability